CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...